September 2022 Issue Table Of Contents

From The Editor

• A D&I Program Worth Replicating

Feature Articles

• Bayer Brings External Innovation Inside, With Guardrails
• Conducting A Drug Development Orchestra To Treat Mental Illness

CEO Corner

• Our Long Journey To FDA Approval

Companies To Watch

• Viking Therapeutics

Industry Research

• Volume Of Trials With Outsourced Clinical Logistics

Podcast Summary

• The “Liberation” Of Science Yields A New Class Of Biopharma Leadership

Inside The Industry

• Is AI/ML Bringing Medicines To Patients Faster And Cheaper?
• Life Sciences CIO Survey Illuminates Tech Trends
• Overlooking Building A Compelling Corporate Narrative Is A Big Mistake
• In A Tighter VC Environment, Biopharmas Need To Get Valuation Right
• Nonprofit Pursues Oncology Drugs
• Making An Unapprovable Drug Product Approvable
• The Case For Implementing TransCelerate's Modernization Of Statistical Analysis Framework

Industry Leader

• How To Advance A Disruptive Therapeutic Approach
• The Secret To The Modern CFO’s Success
• Why Biopharma Needs To Catch Up On Lean Practices And Continuous Learning

Leadership Lessons

• The Paradox Of Connection, How We Can Disconnect To Connect

Ask The Board

• What Can Preclinical Or Early-Stage Biotech Companies Do In The Current Market To Better Access Needed Capital And Resources?
• How Can Biopharma Companies Effectively Maintain Quality And Manage Risk While Rapidly Scaling Up Operations?
• What Can Small Biotech Companies Do To Prepare For Worsening Macroeconomic Conditions?